Sign In
Free Newsletter
BioCentric acquired by global PR firm
Sherine Aly, who founded the Collingswood-based agency in 2001, will continue to lead the new JPA Health division as executive vice president, medical communications.
OPINION: Beware of new regs
The president and CEO of the HealthCare Institute of New Jersey says "recent policy changes by the Federal Trade Commission and Department of Justice could jeopardize our state’s status as a health care leader."
Done deal: Provident finalizes $1.3B merger with Lakeland Bank
The combined company also announced its new leadership team, including former Lakeland President and CEO Thomas Shara, who will serve now serve as executive vice chairman.
Quest plans to purchase PathAI’s diagnostic lab as part of AI ramp-up
“AI and digital technologies have tremendous potential to improve cancer care, and Quest has the know-how to scale and deliver innovations that are high quality, efficient and broadly accessible," said Quest Senior Vice President of Oncology Kristie Dolan.
Banker-turned-landscape-company owner shares why she decided to sell
For more than 80 years, Siciliano Landscape Co. operated as an independent, family-run business. It's now part of a much larger firm. Karen Siciliano, who's still in charge, talks about the sale, how it unfolded and what the integration process was like.
$1.3B Provident-Lakeland merger lands required approvals (updated)
The deal, which is now expected to close May 15, would make the combined bank the seventh largest insured depository institution in New Jersey and the 83rd largest in the U.S.
Private equity to acquire Inrad Optics for $19M
If the deal with Luxium Solutions is approved, the Northvale manufacturer would continue to operate under the same brand and maintain its current Garden State headquarters. Its common stock would no longer be publicly listed.
ZRG adds Ohio search firm to growing portfolio
The target, Wiser Partners, focuses on all industries, specializing in digital marketing and e-commerce executives, according to the Rochelle Park-based buyer.
Bristol Myers Squibb closes $14B Karuna deal
The "acquisition recognizes the enormous potential of KarXT," the Boston-based target's potential first-in-class treatment for schizophrenia in adults.
Choice checks out of Wyndham takeover bid
"The Wyndham Board is pleased that Choice has ended its hostile pursuit and proxy contest, following the expiration of its unsolicited exchange offer," Chairman Stephen Holmes said in a statement.
Merck closes $650M Harpoon acquisition
The transaction brings on additional assets to expand the Rahway-based biopharmaceutical's immuno-oncology research and pipeline.
Johnson & Johnson closes $2B Ambrx acquisition
The deal will allow the New Brunswick-based buyer the opportunity to create and commercialize oncology therapeutics by leveraging the target's proprietary technology.
